{"entity":{"id":"nct05503888","kind":"trial","name":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of aumolertinib and retlirafusp alfa in lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., not yet recruiting.","summary":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer is a phase 1/2, randomised interventional study registered as NCT05503888 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with a registry enrolment figure of 160 participants, started 2022-10-01 and due to reach its primary completion in 2027-07-30. Interventions recorded: Almonertinib combined with SHR-1701; Almonertinib. Conditions listed: Relapsed or Advanced Non-small Cell Lung Cancer. Primary outcome: Dose limiting toxicity （Phase Ib）; The incidence and severity of ≥ grade 3 treatment-related adverse events (TRAE) and serious adverse events (TRSAE) in the combination of two drugs （Phase Ib）; PFS rate at 12 months. Lung eligibility wording from the registry: \"Advanced NSCLC diagnosed by histology or cytology, or recurrent NSCLC after radical treatment such as surgery, radiotherapy, chemoradiotherapy\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05503888","url":"https://clinicaltrials.gov/study/NCT05503888"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["aumolertinib","retlirafusp-alfa"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05503888","phase":"1/2","setting":"An Open-label, Multicenter Phase Ib/II Clinical Study of Almonertinib Combined With SHR-1701 or Other Innovative Drugs in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer With EGFR Mutation","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05503888/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/"},{"id":"retlirafusp-alfa","kind":"drug","name":"Retlirafusp alfa","route":"/drugs/retlirafusp-alfa/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}